{"prompt": "['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', 'IMWG Response Criteria', 'Response Subcategory', 'Response Criteria', 'Appearance of any other sign of progression (ie, new', 'plasmacytoma, lytic bone lesion, or hypercalcaemia)', 'Abbreviations: ASCT = autologous stem-cell transplantation; CR = complete response; CRAB features = calcium elevation,', 'renal failure, anemia, lytic bone lesions; CT = computed tomography; DOR = duration of response; FDG =', 'fluorodeoxyglucose; FLC = free light chain; hr = hour; Ig = immunoglobulin; IMWG = International Myeloma Working', 'Group; MM = multiple myeloma; MR = minimal response; MRD = minimal residual disease; MRI = magnetic resonance', 'imaging; NGF = next-generation flow; NGS = next-generation sequencing; PD = progressive disease; PET = positron', 'emission tomography; PFS = progression-free survival; PR = partial response; sCR = stringent complete response; SD', '=', 'stable disease; SPD = sum of the products of the maximal perpendicular diameters of measured lesions; VGPR = very good', 'partial response.', 'Source: Kumar, 2016 (Kumar 2016).', 'a All response categories require 2 consecutive assessments made any time before starting any new therapy; for', 'MRD there is no need for 2 consecutive assessments, but information on MRD after each treatment stage is', 'recommended (eg, after induction, high-dose therapy/ASCT, consolidation, maintenance). MRD tests should', 'be', 'initiated only at the time of suspected CR. All categories of response and MRD require no known evidence of', 'progressive or new bone lesions if radiographic studies were performed. However, radiographic studies are not', 'required to satisfy these response requirements except for the requirement of FDG PET if imaging MRD-negative', 'status is reported.', 'b Per IMWG, quantitative Ig levels by nephelometry may be used in place of SPEP for routine M-protein', 'measurement for patients with IgA or IgD myeloma. Also, per IMWG, response may be confirmed if the patient', 'fails to provide 24-hour urine sample collection after screening activities occur. See \"Practical considerations for', 'application of IMWG consensus criteria\" section of the guidelines (page e340 in Kumar [Kumar 2016]).', 'c', 'Derived from international uniform response criteria for MM (Durie 2006). MR definition and clarifications', 'derived from Rajkumar (Rajkumar 2011 Rajkumar 2011 Rajkumar 2011). When the only method to measure', 'disease is by serum FLC levels: CR can be defined as a normal FLC ratio of 0.26 to 1.65 in addition to the CR', 'criteria listed previously. VGPR in such patients requires a 90% decrease in the difference between involved and', 'uninvolved FLC levels. All response categories require 2 consecutive assessments made at any time before the', 'institution of any new therapy; all categories also require no known evidence of progressive or new bone lesions or', 'extramedullary plasmacytomas if radiographic studies were performed. Radiographic studies are not required to', 'satisfy these response requirements. Bone marrow assessments do not need to be confirmed. Each category, except', 'for SD, will be considered unconfirmed until the confirmatory test is performed. The date of the initial test is', 'considered as the date of response for evaluation of time dependent outcomes such as DOR.', 'd', 'All recommendations regarding clinical uses relating to serum FLC levels or FLC ratio are based on results', 'obtained with the validated Freelite test (Binding Site, Birmingham, United Kingdom).', 'e', 'Presence/absence of clonal cells on immunohistochemistry is based upon the K/N/L ratio. An abnormal K/N ratio by', 'immunohistochemistry requires a minimum of 100 plasma cells for analysis. An abnormal ratio reflecting presence', 'of an abnormal clone is K/N of >4:1 or <1:2.', 'f', 'Plasmacytoma measurements should be taken from the CT portion of the PET/CT, or MRI scans, or dedicated CT', 'scans where applicable. For patients with only skin involvement, skin lesions should be measured with a ruler.', 'Measurement of tumor size will be determined by the SPD.', 'g', 'Positive immunofixation alone in a patient previously classified as achieving a CR will not be considered', 'progression. For purposes of calculating time-to-progression and PFS, patients who have achieved a CR and are', 'MRD-negative should be evaluated using criteria listed for PD. Criteria for relapse from a CR or relapse from', 'MRD should be used only when calculating disease-free survival.', 'h', 'In the case where a value is felt to be a spurious result per Investigator discretion (eg, a possible laboratory error),', 'that value will not be considered when determining the lowest value.', 'Confidential', 'Page 77', 'Version 4.0']['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', 'Questions regarding interpretation of the IMWG criteria (Table 17) may be addressed by', 'consulting the, \"Practical considerations for application of IMWG consensus criteria,\" section of', 'the guidelines (page e340 in Kumar (Kumar 2016).', '11.3.1.1. SPEP', 'SPEP with monoclonal protein band (M-spike) quantification and serum protein immunofixation', 'will be performed to assess response.', '11.3.1.2. UPEP', 'UPEP (24-hour urine) with M-spike quantification and urine protein immunofixation will be', 'performed to assess response. UPEP must be determined from a urine sample collected for', '24 hours - no other method is acceptable.', 'UPEP must be performed at each time point outlined in the protocol even if the patient is being', 'followed by SPEP.', '11.3.1.3. Quantitative Immunoglobulin Levels', 'If SPEP is felt to be unreliable for routine M-protein measurement (eg, patients with IgA or IgD', 'myeloma), then quantitative Ig levels by nephelometry is acceptable. However, this must be', 'explicitly reported, and even though nephelometry can be used for the patient to assess response,', 'SPEP and nephelometric values cannot be used interchangeably (Durie 2006).', '11.3.1.4. Serum FLC', 'Serum FLC will be performed to assess response.', 'For patients whose disease is only measurable by serum FLC:', 'CR requires negative serum and urine immunofixation plus a normal serum FLC ratio', 'of 0.26 to 1.65 on 2 consecutive assessments. Laboratories may use their own', 'reference ranges.', 'VGPR requires >90% decrease in the difference between involved and uninvolved', 'serum FLC levels on 2 consecutive assessments.', '11.3.1.5. \u00df2 microglobulin', '\u00df2 microglobulin will be performed for MM staging (Table 14) and will not be used to assess', 'response.', '11.3.1.6. LDH', 'Serum LDH will be performed for MM staging (Table 14).', '11.3.1.7. Skeletal Survey', 'A baseline skeletal survey will be performed using X-rays and/or other clinically appropriate', 'imaging modalities (eg, magnetic resonance imaging ([MRI], whole body computed tomography', '[CT], or positron emission tomography [PET]/CT) as determined by the Investigator.', 'Confidential', 'Page 78', 'Version 4.0']\n\n###\n\n", "completion": "END"}